<?xml version="1.0" encoding="utf-8"?>
<resources>

    <string name="app_name">EP Mobile</string>
    <string name="about_text">EP Mobile is a package of
		useful cardiac electrophysiology
		tools for your Android phone or tablet.
		These tools are for reference purposes only
		and are not meant to substitute for clinical judgment.
		If you have suggestions or comments, please contact us.
		\n\nEmail: mannd@epstudiossoftware.com
		\nWeb: www.epstudiossoftware.com
		\n\nCopyright \u00a9 2011 EP Studios, Inc.
		\nLicensed under GNU GPL v3.
  </string>
    <string name="main_index_title">EP Mobile</string>
    <string name="about_label">About</string>
    <string name="about_title">About EP Mobile</string>
    <string name="dofetilide_label">Dofetilide Calculator</string>
    <string name="dofetilide_calculator_title">Dofetilide Calculator</string>
    <string name="dabigatran_calculator_title">Dabigatran Calculator</string>
    <string name="dabigatran_label">Dabigatran Calculator (US Dosing)</string>
    <string name="qtc_calculator_title">QTc Calculator</string>
    <string name="cycle_length_label">Cycle Length Calculator</string>
    <string name="cycle_length_calculator_title">Cycle Length Calculator</string>
    <string name="rr_label">RR Interval (msec)</string>
    <string name="rr_hint">RR (msec)</string>
    <string name="interval_rate_title">Interval or Rate</string>
    <string name="interval_rate_summary">Use RR interval or heart rate as default</string>
    <string name="qt_label">QT Interval (msec)</string>
    <string name="qt_hint">QT (msec)</string>
    <string name="qtc_result_label">QTc (msec)</string>
    <string name="calculate_label">Calculate!</string>
    <string name="clear_label">Clear</string>
    <string name="cleared">Cleared!</string>
    <string name="dose_result_label">Dose</string>
    <string name="weight_hint">Weight (kg)</string>
    <string name="weight_lb_hint">Weight (lb)</string>
    <string name="creatinine_hint">Creatinine (mg/dL)</string>
    <string name="age_hint">Age (yr)</string>
    <string name="age_label">Age (yr)</string>
    <string name="weight_label">Weight (kg)</string>
    <string name="creatinine_label">Creatinine (mg/dL)</string>
    <string name="creatinine_clearance_label"></string>
    <string name="male_label">Male</string>
    <string name="female_label">Female</string>
    <string name="cl_label">Cycle Length (msec)</string>
    <string name="cl_hint">CL (msec)</string>
    <string name="hr_label">Heart Rate (bpm)</string>
    <string name="hr_hint">HR (bpm)</string>
    <string name="calculated_result_label"></string>
    <string name="qtc_formula_title">QTc Formula</string>
    <string name="qtc_formula_summary">Select the QTc formula</string>
    <string name="maximum_qtc_title">Maximum QTc</string>
    <string name="maximum_qtc_summary">Enter the maximum QTc in msec</string>
    <string name="maximum_qtc_message">This value is used to
		color code (with red) abnormally high QTc values</string>
    <string name="maximum_qtc_default_value">440</string>
    <string name="settings_label">Settings...</string>
    <string name="settings_shortcut">s</string>
    <string name="settings_title">EP Mobile Settings</string>
    <string name="hasbled_title">HAS-BLED Score</string>
    <string name="htn_label">Hypertension (systolic BP \u2267 160)</string>
    <string name="abnormal_renal_label">Abnormal renal function
		(dialysis, kidney transplant, Cr \u2267 2.6 mg/dL)</string>
    <string name="abnormal_liver_label">Abnormal liver function</string>
    <string name="stroke_label">Previous stroke history</string>
    <string name="bleeding_label">Major bleeding history</string>
    <string name="labile_inr_label">Labile INRs (high INRs, or &lt;60%
		of time in therapeutic range)</string>
    <string name="age65_label">Age 65 or over</string>
    <string name="drug_label">Taking antiplatelet drugs
		(e.g. ASA, Plavix)</string>
    <string name="etoh_label">Alcohol intake (8 or more drinks per week)
  </string>
    <string name="normal_hasbled">Low bleeding risk</string>
    <string name="abnormal_hasbled">High bleeding risk</string>
    <string name="chads_title">CHADS\u2082 Score</string>
    <string name="chf_label">Congestive heart failure</string>
    <string name="age75_label">Age 75 or over</string>
    <string name="diabetes_label">Diabetes mellitus</string>
    <string name="low_chads_message">Anti-platelet drug (ASA) recommended
  </string>
    <string name="medium_chads_message">Anti-platelet drug or
		anticoagulation (warfarin, dabigatran or rivaroxaban) recommended</string>
    <string name="high_chads_message">
		Anticoagulation (warfarin, dabigitran or rivaroxaban) recommended
  </string>
    <string name="chadsvasc_title">CHA\u2082DS\u2082-VASc Score</string>
    <string name="vascular_label">Vascular disease (e.g. PVD, CAD, aortic plaque)
	</string>
    <string name="low_chadsvasc_message">No antithrombotic therapy or use Aspirin</string>
    <string name="medium_chadsvasc_message">Oral anticoagulation (warfarin or dabigatran
		or others) or Aspirin (Oral anticoagulant preferred)</string>
    <string name="high_chadsvasc_message">Oral anticoagulation
		(warfarin or dabigatran or others)</string>
    <string name="warfarin_title">Warfarin Calculator</string>
    <string name="warfarin_label">Warfarin Dose Calculator</string>
    <string name="tablet_label">Tablet</string>
    <string name="tablet1">2 mg</string>
    <string name="tablet2">2.5 mg</string>
    <string name="tablet3">5 mg</string>
    <string name="tablet4">7.5 mg</string>
    <string name="inr_label">INR</string>
    <string name="weekly_dose_label">Current total warfarin dose per week</string>
    <string name="inr_hint">INR</string>
    <string name="weekly_dose_hint">Dose (mg/week)</string>
    <string name="inr_target_label">INR target</string>
    <string name="inr_target1">2.0 - 3.0</string>
    <string name="inr_target2">2.5 - 3.5</string>
    <string name="default_warfarin_tablet_title">Default Warfarin Tablet</string>
    <string name="default_warfarin_tablet_summary">Select the default warfarin tablet strength
	</string>
    <string name="default_inr_target_title">Default INR Target</string>
    <string name="default_inr_target_summary">Default INR target range</string>
    <string name="dose_table_title">Suggested Weekly Warfarin Doses</string>
    <string name="warfarin_result_title">Suggested Warfarin Dosing</string>
    <string name="warfarin_reference">Reference: Horton J, Bushwick B: American Family
		Physician. Feb 1, 1999.
		http://www.aafp.org/afp/990201ap/635.html</string>
    <string name="wct_algorithm_list_title">Wide Complex Tachycardia \u25B6</string>
    <string name="wct_algorithm_title">Wide Complex Tachycardia</string>
    <string name="brugada_vt_title">Brugada Criteria SVT vs VT</string>
    <string name="brugada_wct_title">Brugada Algorithm</string>
    <string name="brugada_step_1">Absence of an RS complex in all precordial leads?
	</string>
    <string name="brugada_step_2">R to S interval >100 msec in one precordial lead?
	</string>
    <string name="brugada_step_3">AV dissociation?</string>
    <string name="brugada_step_4">Morphology criteria for VT present in both
		precordial leads V1-2 and V6?</string>
    <string name="vt_result">Wide complex tachycardia is most likely Ventricular
		Tachycardia.</string>
    <string name="svt_result">Wide complex tachycardia is most likely
		Supraventricular Tachycardia.</string>
    <string name="brugada_reference">REFERENCE: Brugada P, et al. Circ 1991;83:1649.
	</string>
    <string name="wct_result_label">WCT Result</string>
    <string name="yes">Yes</string>
    <string name="no">No</string>
    <string name="back">Back</string>
    <string name="done_label">Done</string>
    <string name="reset_label">Reset</string>
    <string name="morphology_label">Morphology Criteria</string>
    <string name="morphology_title">@string/morphology_label</string>
    <string name="broad_r">R > 30 msec in V1 or V2</string>
    <string name="broad_rs">Onset to nadir S > 60 msec in V1 or V2</string>
    <string name="notched_s">Notched or slurred S in V1 or V2</string>
    <string name="q_v6">QR or QS in V6</string>
    <string name="monophasic_r_v1">Monophasic R in V1</string>
    <string name="qr_v1">QR in V1</string>
    <string name="rs_v1">RS in V1</string>
    <string name="deep_s_v6">R to S ratio &lt; 1 in V6</string>
    <string name="monophasic_r_v6">Monophasic R in V6</string>
    <string name="rwpt_title">R Wave Peak Time Criterion</string>
    <string name="rwpt_text">R wave peak time in lead II (RWPT).
		Measure the onset of the QRS in ECG lead II to the first
		change in polarity (nadir Q or peak R). RWPT \u2265 50 msec
		strongly suggests VT (positive likelihood ratio 34.8).
		Reference: Pava LF, et al. Heart Rhythm 2010;7:922.</string>
    <string name="rbbb_wct_label">"RBBB" Tachycardia</string>
    <string name="lbbb_wct_label">"LBBB" Tachycardia</string>
    <string name="wellens_reference">
		From Wellens et al. Am J Med 1978;64:27.</string>
    <string name="normal_ep_values_title">Normal EP Values</string>
    <string name="basic_intervals_label">Basic Conduction Intervals</string>
    <string name="sinus_node_label">Sinus Node Function</string>
    <string name="refractory_periods_label">Refractory Periods and Block Cycle Lengths
  </string>
    <string name="normal_ep_values_reference">Reference: Josephson ME. Clinical Cardiac
		Electrophysiology. Techniques and Interpretations. 2nd Edition 1993.
		Lea &amp; Febiger.
  </string>
    <string name="arvc_title">ARVC/D Diagnosis</string>
    <string name="global_dysfunction_label">I. Global or regional dysfunction and structural
		alterations</string>
    <string name="major">MAJOR</string>
    <string name="minor">MINOR</string>
    <string name="by_echo_label">By 2D echo:</string>
    <string name="regional_echo_abnormality_label">Regional RV akinesia, dyskinesia, or aneurysm
	</string>
    <string name="regional_echo_minor_abnormality_label">Regional RV akinesia or dyskinesia</string>
    <string name="regional_mri_abnormality_label">Regional RV akinesia or dyssynchronous RV
		contraction</string>
    <string name="and_one_echo_label">and one of the following (end diastole)...</string>
    <string name="and_one_label">and one of the following...</string>
    <string name="major_plax_criteria">PLAX RVOT \u2265 32 mm (corrected for body size
		[PLAX/BSA] \u2265 19 mm/m\u00b2)</string>
    <string name="major_psax_criteria">PSAX RVOT \u2265 36 mm (corrected for body size
		[PSAX/BSA] \u2265 21 mm/m\u00b2)</string>
    <string name="fractional_area_criteria">fractional area change \u2264 33%</string>
    <string name="minor_plax_criteria">PLAX RVOT \u2265 29 to \u003c 32 mm (corrected for
		body size
		[PLAX/BSA] \u2265 16 to \u003c 19 mm/m\u00b2)</string>
    <string name="minor_psax_criteria">PSAX RVOT \u2265 32 to \u003c 36mm (corrected for
		body size
		[PSAX/BSA] \u2265 18 to \u003c 21 mm/m\u00b2)</string>
    <string name="fractional_area_minor_criteria">fractional area change \u003e 33%
		and \u2264 40%</string>
    <string name="by_mri_label">By MRI:</string>
    <string name="major_mri_volume_criteria">Ratio of RV end-diastolic volume to BSA \u2265 110
		mL/m\u00b2
		(male) or \u2265 100 mL/m\u00b2 (female)</string>
    <string name="major_mri_ef_criteria">RV ejection fraction \u2264 40%</string>
    <string name="minor_mri_volume_criteria">Ratio of RV end-diastolic volume to BSA \u2265 100
		to
		\u003c 110 mL/m\u00b2 (male) or \u2265 90 to \u003c 100 mL/m\u00b2 (female)
	</string>
    <string formatted="false" name="minor_mri_ef_criteria">RV ejection fraction \u003e 40% to \u2264 45%
	</string>
    <string name="by_rv_angio_label">By RV Angiography:</string>
    <string name="tissue_label">II. Tissue characterization of wall</string>
    <string formatted="false" name="major_residual_myocytes_label">
		Residual myocytes \u003c 60% by morphometric
		analysis (or \u003c 50% if estimated) with fibrous replacement of RV
		free wall myocardium in \u2265 1 sample, with or without fatty
		replacement of tissue on endomyocardial biopsy</string>
    <string formatted="false" name="minor_residual_myocytes_label">
		Residual myocytes 60% to 75% by morphometric
		analysis (or 50% to 65% if estimated) with fibrous replacement of RV
		free wall myocardium in \u2265 1 sample, with or without fatty
		replacement of tissue on endomyocardial biopsy</string>
    <string name="repolarization_label">III. Repolarization abnormalities</string>
    <string name="major_repolarization_label">TWI (V1, V2, and V3) or beyond in
	individuals \u003e 14 yrs (in absence of complete RBBB)</string>
    <string name="minor_repolarization_no_rbbb_label">TWI in V1 and V2
	in individuals \u003e 14 yrs (in absence of complete RBBB) or in V4, V5, V6</string>
    <string name="minor_repolarization_rbbb_label">TWI in V1-V4 in
	individuals \u003e 14 yrs in presence of complete RBBB</string>
    <string name="depolarization_label">IV. Depolarization/conduction abnormalities
	</string>
    <string name="major_depolarization_label">Epsilon wave (reproducible low-amp signals between
	end of QRS complex to onset of T wave) in right precordial leads (V1-V3)</string>
    <string name="saecg_label">LP by SAECG in \u2265 1 of 3 parameters in 
	absence of QRS duration of \u2265 110 msec on standard ECG</string>
    <string name="filtered_qrs_label">Filtered QRS duration (fQRS) \u2265 114 msec</string>
    <string name="duration_terminal_qrs_label">Duration of terminal QRS \u003c 40 \u03bcV
	(low-amplitude signal duration) \u2265 38 msec</string>
    <string name="root_mean_square_label">Root-mean-square voltage of terminal 40 msec \u2264 20 \u03bcV
	</string>
    <string name="terminal_activation_label">Terminal activation duration</string>
    <string name="terminal_activation_duration_label">Terminal activation duration of QRS
	\u2265 55 msec measure from the nadir of the S wave to the end of the QRS including
	R\', in V1, V2, or V3, in the absence of complete RBBB</string>
    <string name="arrhythmias_label">V. Arrhythmias</string>
    <string name="major_arrhythmias_label">Nonsustained or sustained VT of LBBB morphology
	with superior axis (negative or indeterminate QRS in leads II, III, and aVF and
	positive in lead aVL)</string>
    <string name="rvot_vt_label">Nonsustained or sustained VT of RV outflow configuration,
	LBBB morphology with inferior axis (positive QRS in leads II, III, and aVF and negative
	in lead aVL) or of unknown axis</string>
    <string name="pvcs_label">\u003e 500 ventricular extrasystoles per 24 hours (Holter)
	</string>
    <string name="family_history_label">VI. Family history</string>
    <string name="first_degree_relative_label">ARVC/D confirmed in a first-degree relative
	who meets current Task Force criteria</string>
    <string name="pathology_label">ARVC/D confirmed pathologically at autopsy or surgery 
	in a first-degree relative</string>
    <string name="genetic_label">Identification of a pathogenic mutation categorized
	as associated or probably associated with ARVC/D in the patient under evaluation
	</string>
    <string name="possible_family_history_label">History of ARVC/D in a first-degree
	relative in whom it is not possible or practical to determine whether the family
	member meets current Task Force criteria</string>
    <string name="family_history_sudden_death_label">Premature sudden death (\u003c 35
	years of age) due to suspected ARVC/D in a first-degree relative</string>
    <string name="second_degree_relative_label">ARVC/D confirmed pathologically or by 
	current Task Force Criteria in a second-degree relative</string>
    <string name="arvc_key">BSA = body surface area. PLAX = parasternal long
		axis view. PSAX = parasternal short
		axis view. RVOT = RV outflow tract.</string>
    <string name="arvc_reference">Reference: Marcus FI et al. Circulation
		2010;121:1533.
		http://circ.ahajournals.org/content/121/13/1533.long</string>
    <string name="qtc_settings">QTc Settings</string>
    <string name="warfarin_settings">Warfarin Settings</string>
    <string name="drug_calculator_settings">Drug Calculator Settings</string>
    <string name="default_weight_unit_title">Default Weight Unit</string>
    <string name="default_weight_unit_summary">Select default unit for weight</string>
    <string name="creatine_clearance_label">Creatinine Clearance</string>
    <string name="dabigatran_warning_severe">Avoid concomitant use of P-gp inhibitors
	    (e.g. dronedarone).</string>
    <string name="dabigatran_warning_mild">Consider reducing dose of dabigatran to 75 mg twice a day 
	    when dronedarone or systemic ketoconazole is administered with dabigatran.</string>
    <string name="rivaroxaban_calculator_title">Rivaroxaban Calculator</string>
    <string name="rivaroxaban_dosing_message">"Take dose with evening meal."</string>
    <string name="icd_calculator_title">CMS ICD Criteria</string>
    <string name="short_qt_title">Short QT Syndrome Diagnosis</string>
    <string name="qtc_label">QTc Interval</string>
    <string name="short_qt_label">\u003c 370 msec</string>
    <string name="shorter_qt_label">\u003c 350 msec</string>
    <string name="shortest_qt_label">\u003c 330 msec</string>
    <string name="jt_label">Jpoint-Tpeak Interval</string>
    <string name="short_jt_label">\u003c 120 msec</string>
    <string name="clinical_history_label">Clinical History</string>
    <string name="sudden_cardiac_arrest_label">Sudden cardiac arrest</string>
    <string name="polymorphic_vt_label">Polymorphic VT or VF</string>
    <string name="unexplained_syncope_label">Unexplained syncope</string>
    <string name="afb_label">Atrial fibrillation</string>
    <string name="family_hx_label">Family History</string>
    <string name="relative_with_sqts_label">1st or 2nd degree relative with SQTS</string>
    <string name="relative_with_sd_label">1st or 2nd degree relative with sudden death</string>
    <string name="sids_label">Sudden infant death syndrome</string>
    <string name="genotype_label">Genotype</string>
    <string name="genotype_positive_label">Genotype positive</string>
    <string name="mutation_label">Mutation of undetermined significance
	    in a culprit gene</string>
    <string name="sqts_reference">Gollob M, et al. J Am Coll Cardiol 2011;57:802.</string>
    <string name="instructions_label">Instructions</string>
    <string name="sqts_instructions">Electrocardiogram must be recorded in the absence of modifiers
	    known to shorten the QT.  Jpoint-Tpeak interval must be measured in the precordial lead
	    with the greatest amplitude T-wave.  Clinical history: events must occur in the absence of
	    an identifiable etiology, including structural heart disease.  Note that at least one ECG
	    manifestation must be present in order to get additional points.</string>
    <string name="drug_dose_calculator_list_title">Drug Dose Calculators \u25B6</string>
    <string name="drug_dose_calculators_title">Drug Dose Calculators</string>
    <string name="risk_score_list_title">Risk Scores \u25B6</string>
    <string name="risk_scores_title">Risk Scores</string>

    <!-- HCM -->
    <string name="hcm_title">HCM Sudden Death Risk Score</string>
    <!-- Major risk factors -->
    <string name="cardiac_arrest_label">Cardiac arrest (VF)</string>
    <string name="spontaneous_vt_label">Spontaneous sustained VT</string>
    <string name="family_hx_sd_label">Family history of premature SD</string>
    <!-- unexplained_syncope_label -->
    <string name="lv_thickness_label">LV thickness \u2265 30 mm</string>
    <string name="abnormal_exercise_bp_label">Abnormal exercise BP</string>
    <string name="nonsustained_vt_label">Nonsustained VT (Holter)</string>
    <!-- Minor risk factors -->
    <!-- afb_label -->
    <string name="myocardial_ischemia_label">Myocardial ischemia</string>
    <string name="lv_outflow_obstruction_label">LV outflow obstruction</string>
    <string name="high_risk_mutation_label">High-risk mutation</string>
    <string name="hcm_highest_risk_sd_text">Survivors of cardiac arrest and patients
	    with spontaneous sustained VT are considered at very high risk for SD and are
	    ICD candidates</string>
    <string name="hcm_high_risk_text">Patients with 2 or more major risk factors are
	    considered at high risk and should be considered for ICD implantation.</string>
    <string name="hcm_intermediate_risk_text">Patients with 1 major risk factor have 
	    increased risk for SD and recommendations should be individualized.
	    Factors such as the nature of the risk factor (e.g. SD in an immediate family
	    member with HCM), young age (which confers greater risk) and presence of minor risk
	    factors should be considered.  ICD implantation can be considered depending
	    on these factors.</string>
    <string name="hcm_low_risk_text">Patients without any major risk factors (even if
	    minor risk factors are present) are considered to be at low risk for SD.
	    ICD implantation is not recommended.</string>
    <string name="hcm_key">BP = blood pressure. VF = ventricular fibrillation.  VT = ventricular tachycardia.
	    SD = unexpected sudden death.  Abnormal exercise BP = failure to augment and maintain systolic
	    BP \u003e 25 mm Hg with exercise.</string>
    <string name="hcm_reference">References: Maron B et al.  Eur Heart J 2003:1965.
	    http://eurheartj.oxfordjournals.org/content/24/21/1965.full
	    McKenna WJ et al. Heart 2002;87:169.
	    http://heart.bmj.com/content/87/2/169.full
		</string>

    <!-- ICD CMS criteria -->
    <string name="secondary_prevention_label">Secondary Prevention</string>
    <string name="icd_cardiac_arrest_label">Documented cardiac arrest, without transient or reversible cause</string>
    <string name="icd_sus_vt_label">Documented sustained VT/VF, either spontaneous or induced at EPS, not associated with an acute MI, 
	     and without transient or reversible cause</string>
    <string name="primary_prevention_label">Primary Prevention</string>
    <string name="icd_familial_conditions_label">Documented familial or inherited condition 
        with a high risk of life-threatening VT, e.g. Long QT Syndrome or HCM</string>
    <string name="icd_nonischemic_cm_label">Nonischemic cardiomyopathy</string>
    <string name="icd_ischemic_cm_label">Ischemic cardiomyopathy</string>
    <string name="icd_ef_gt_35_label">EF \u003e 35%</string>
    <string name="icd_ef_lt_35_label">EF \u003e 30% and \u2264 35%</string>
    <string name="icd_ef_lt_30_label">EF \u2264 30%</string>
    <string name="icd_mi_label">Documented prior MI</string>
    <string name="icd_nyha1_label">NYHA class I</string>
    <string name="icd_nyha2_label">NYHA class II</string>
    <string name="icd_nyha3_label">NYHA class III</string>
    <string name="icd_nyha4_label">NHYA class IV</string>
    <string name="icd_short_duration_cm_label">CM duration \u003c 3 months</string>
    <string name="icd_long_duration_cm_label">CM duration \u2265 3 months</string>
    <string name="icd_inducible_vt_label">Inducible sustained VT/VF at EPS</string>
    <string name="icd_qrs_duration_short_label">QRS duration \u003c 120 msec</string>
    <string name="icd_qrs_duration_long_label">QRS duration \u2265 120 msec</string>
    <string name="exclusions_label">Exclusions</string>
    <string name="icd_cardiogenic_shock_label">Cardiogenic shock or symptomatic hypotension</string>
    <string name="icd_recent_cabg_label">CABG or PCI within past 3 months</string>
    <string name="icd_recent_mi_label">Acute MI within past 40 days</string>
    <string name="icd_recent_mi_eps_label">EPS performed within 4 weeks post-MI</string>
    <string name="icd_revascularization_candidate_label">Symptoms or findings that would make patient a candidate for revascularization</string>
    <string name="icd_brain_damage_label">Irreversible brain damage from preexisting cerebral disease</string>
    <string name="icd_bad_prognosis_label">Non-cardiac disease with likelihood of survival \u003c 1 year</string>
    <string name="icd_no_ef_or_nyha_message">Invalid. You must select an EF and
        NYHA class.</string>
    <string name="icd_no_ef_message">Invalid. You must select an EF.</string>
    <string name="icd_no_nyha_message">Invalid. You must select a NYHA class.</string>
    <string name="icd_approved_text">ICD implantation appears to meet CMS guidelines.</string>
    <string name="icd_not_approved_text">ICD implantation does NOT meet CMS guidelines.</string>
    <string name="icd_crt_approved_text">CRT-ICD implantation appears to meet CMS guidelines.</string>
    <string name="crt_approved_text">Use of a CRT-ICD may be indicated.</string>
    <string name="post_mi_time_exclusion">ICD implantation is too soon post MI.</string>
    <string name="post_mi_early_eps_exclusion">EPS performed too soon post MI.</string>
    <string name="absolute_exclusion">ICD implantation has one or more exclusions.</string>
    <string name="brain_damage_exclusion">Irreversible brain damage is an absolute exclusion 
        for ICD implantation.</string>
    <string name="post_revascularization_exclusion">ICD implantation is too soon post myocardial revascularization.</string>
    <string name="cms_icd_instructions">The Calculate button will show whether the patient is likely 
         to meet CMS guidelines for Medicare reimbursement.  Note the CMS National Coverage Determination
         (NCD) is quite detailed and you should be very familiar with it before making a decision 
	     as to whether a particular patient is likely to be
	     covered.  This module is only intended as a guide to the NCD and is not definitive.
	     Additional factors need to be considered.  For example, the NCD definition of 
	     myocardial infarction must be used. Primary prevention ICD recipients 
	     must be enrolled in an FDA-approved clinical trial
	     or in the National ICD Registry.  Although unstated in CMS guidelines, patients
	     considered for primary prevention ICDs should be on stable, optimal medical
	     therapy for left ventricular dysfunction.  Note also that the CMS 
	     makes a distinction between EP testing performed for suspected VT (e.g. in a patient with syncope) in Guideline #2
	     and EP testing performed for risk stratification (e.g. as in MADIT), which is Guideline #4.
	     The CMS NCD does not cover approval of CRT devices.  
	     CRT device approval is subject to Local Coverage Determinations and
         local payers.  Note that some locales may require
         QRS duration \u2265 130 msec for CRT coverage.
         </string>
    <string name="cms_icd_key">CABG = coronary artery bypass grafting.  CM = cardiomyopathy. 
        CMS = Centers for Medicare and Medicaid Services.
        CRT = cardiac resynchronization therapy. EF = ejection fraction. EPS = electrophysiology study. 
        HCM = hypertrophic cardiomyopathy. ICD = implantable cardioverter defibrillator.
        MI = myocardial infarction. NYHA = New York Heart Association. PCI = percutaneous coronary intervention. 
        VT = ventricular tachycardia. VF = ventricular fibrillation.</string>
    <string name="cms_icd_references">Reference: Center for Medicaid and Medicare Services, 
	     National Coverage Determination Manual, Chapter 1, Part 1, Section 20.4, 2005.
	     </string>
    <string name="hemorrhages_title">HEMORR\u2082HAGES Score</string>
    <string name="low_risk_hemorrhages">Low risk of bleeding.</string>
    <string name="intermediate_risk_hemorrhages">Intermediate risk of bleeding.</string>
    <string name="high_risk_hemorrhages">High risk of bleeding.</string>
    <string name="hemorrhages_reference">REFERENCE: Gage BF et al. Am Heart J 2006;151:713.</string>
    <string name="hepatic_or_renal_disease_label">Hepatic (cirrhosis, \u2265 2-fold
        elevation of AST or ALT, or albumin &lt; 3.6 g/dL) or renal disease (Cr clearance &lt; 30 ml/min)</string>
    <string name="etoh_hemorrhages_label">Ethanol use (history of EtOH abuse, recent hospitalization for EtOH-related illness, and
	    worsening liver disease</string>
    <string name="malignancy_label">Malignancy (recent metastatic cancer)</string>
    <string name="older_label">Older (age > 75)</string>
    <string name="platelet_label">Reduced platelet count or function (plts &lt; 75,000, scheduled use of antiplatelet
	    therapy, i.e. daily ASA or NSAID Rx, or blood dyscrasia)</string>
    <string name="rebleeding_label">Re-bleeding (prior bleed requiring hospitalization)</string>
    <string name="htn_uncontrolled_label">Hypertension, uncontrolled (BP not currently controlled, 
	    systolic BP \u2265 160)</string>
    <string name="anemia_label">Anemia (most recent Hct &lt; 30 or Hgb &lt; 10 g/dL)</string>
    <string name="genetic_factors_label">Genetic factors (CYP2C9*2 and/or CYP2C9*3)</string>
    <string name="fall_risk_label">Elevated risk of fall including neuropsychiatric disease (Alzheimer, Parkinson,
	    schizophrenia, etc.)</string>
    <string name="stroke_hemorrhages_label">Stroke</string>
    <string name="wpw_algorithm_title">WPW Pathway Location</string>
    <string name="wpw_algorithm_list_title">WPW Pathway Location \u25b6</string>
    <string name="arruda_title">Arruda Algorithm</string>
    <string name="modified_arruda_title">Modified Arruda Algorithm</string>
    <string name="milstein_title">Milstein Algorithm</string>
    <string name="arruda_step_1">Lead I \u00b1 or -\n or V1 R/S \u2265 1?</string>
    <string name="arruda_step_2_3">Pathway is Left Free Wall\nLead aVF + ?</string>
    <string name="arruda_step_6_7">Pathway is Left Free Wall\nLead I \u00b1 or Lead V1 S \u00b1 ?</string>
    <string name="arruda_step_8a">Lead V1 + ?</string>
    <string name="arruda_step_8b">Lead V1 \u00b1 ?</string>
    <string name="arruda_step_13">Lead II - ?</string>
    <string name="arruda_step_15">Lead V1 \u00b1 or - ?</string>
    <string name="arruda_step_16_17">Pathway is Septal\nLead aVF - ?</string>
    <string name="arruda_step_18">Lead aVF \u00b1 ?</string>
    <string name="arruda_step_20">Lead III R \u2265 S ?</string>
    <string name="arruda_step_24_25_26">Pathway is Right Free Wall\nLead aVF + ?</string>
    <string name="arruda_step_27">Lead II + ?</string>
    <string name="pathway_location_label">Accessory Pathway Location</string>
    <string name="show_map_label">Show Map</string>
    <string name="ap_location_message">Accessory pathway location:\n</string>
    <string name="lpl_ll_location">Left Posterolateral or Left Lateral</string>
    <string name="ll_location">Left Lateral</string>
    <string name="lal_location">Left Anterolateral</string>
    <string name="lp_psta_location">Left Posterior or Posteroseptal Tricuspid Annulus</string>
    <string name="lp_lpl_location">Left Posterior or Left Posterolateral</string>
    <string name="ll_lal_location">Left Lateral or Left Anterolateral</string>
    <string name="subepicardial_location">Epicardial: Coronary Sinus or Middle Cardiac Vein</string>
    <string name="psta_psma_location">Posteroseptal Tricuspid Annulus or Posteroseptal Mitral Annulus</string>
    <string name="as_location">Anteroseptal</string>
    <string name="psta_location">Posteroseptal Tricuspid Annulus</string>
    <string name="msta_location">Mid-septal Tricuspid Annulus</string>
    <string name="rp_rpl_location">Right Posterior or Right Posterolateral</string>
    <string name="ra_ral_location">Right Anterior or Right Anterolateral</string>
    <string name="rl_location">Right Lateral</string>
    <string name="undetermined_location">Undetermined Location</string>
    <string name="av_annulus_map_title">Accessory Pathway Location</string>
    <string name="milstein_step_1">Q or isoelectric delta wave in Leads I, aVL, or V6?</string>
    <string name="milstein_step_2_5">LBBB (+ QRS \u2265 90 msec in Lead I and rS in V1 and V2)?</string>
    <string name="milstein_step_3">Q or isoelectric delta wave two of Leads II, III, aVF?</string>
    <string name="milstein_step_4">Rs or RS in V1, V2, or V3?</string>
    <string name="milstein_step_6">QRS axis \u003e +30\u00b0</string>
    <string name="milstein_step_7">Rs or RS in V1 or V2</string>
    <string name="anatomy_av_annulus_title">Anatomy of AV Annulus</string>
    <!-- Long QT -->
    <string name="long_qt_syndrome_diagnosis_title">Long QT Syndrome Diagnosis</string>
    <string name="ecg_findings_label">ECG Findings</string>
    <string name="longest_qt_label">QTc \u2265 480 msec</string>
    <string name="longer_qt_label">QTc 460-470 msec</string>
    <string name="long_qt_label">QTc 450 msec (in males)</string>
    <string name="torsade_label">Torsade de pointes</string>
    <string name="t_wave_alternans_label">T-Wave alternans</string>
    <string name="notched_t_wave_label">Notched T wave in 3 leads</string>
    <string name="low_hr_label">Low heart rate for age*</string>
    <string name="clinical_hx_label">Clinical History</string>
    <string name="syncope_with_stress_label">Syncope with stress</string>
    <string name="syncope_without_stress_label">Syncope without stress</string>
    <string name="congenital_deafness_label">Congenital deafness</string>
    <string name="family_hx_lqt_label">Family members with definite LQTS</string>
    <string name="family_hx_scd_label">Unexplained SCD \u003c age 30 in immediate family</string>
    <string name="lqts_key">ECG findings in absence of medications that affect ECG, 
        LQTS = long QT syndrome, QTc calculated by Bazett formula,
        SCD = sudden cardiac death, *resting heart rate below 2nd percentile for age.
        Note: the same family member cannot be counted more than once.</string>
    <string name="lqts_reference">Schwartz PJ et al.  Circulation 1993;88:782.
        http://circ.ahajournals.org/content/88/2/782.citation</string>
    <!-- ARVC 1994 criteria -->
    <string name="arvc_old_title">ARVC/D 1994 Criteria</string>
    <string name="arvc_old_rv_dilatation">Severe dilataion and reduction
        of RVEF with no or only mild LV impairment</string>
    <string name="arvc_old_rv_aneurysms">Localized RV aneurysms (akinetic
        or dyskinetic areas with diastolic bulging)</string>
    <string name="arvc_old_rv_segmental_dilatation">Sever segmental dilatation
	    of the RF</string>
    <string name="arvc_old_reference">WJ McKenna et al.  Br Heart J. 1994;71:215.
 	    http://www.ncbi.nlm.nih.gov/sites/ppmc/articles/PMC483655/</string>

</resources>